Browse views: by Year, by Function, by GLF, by Subfunction, by Conference, by Journal

Prognostic value of PLAGL1-specific CpG site methylation in soft-tissue sarcomas

Peille, A and Brouste, V and Kauffmann, A and Lagarde, P and Le, M and Coindre, J and Chibon, F and Bresson-Bepoldin, L (2013) Prognostic value of PLAGL1-specific CpG site methylation in soft-tissue sarcomas. PLoS One.

Abstract

Soft tissue sarcomas (STS) are rare, complex tumors with a poor prognosis. The identification of new prognostic biomarkers is needed to improve patient management. Our aim was to determine the methylation status of the 118 CpG sites in the PLAGL1 tumor-suppressor gene P1 CpG island promoter and study the potential prognostic impact of PLAGL1 promoter methylation CpG sites in STS. Training cohorts constituted of 28 undifferentiated sarcomas (US) and 35 leiomyosarcomas (LMS) were studied. PLAGL1 mRNA expression was investigated by microarray analysis and validated by RT-qPCR. Pyrosequencing was used to analyze quantitative methylation of the PLAGL1 promoter. Associations between global promoter or specific CpG site methylation and mRNA expression were evaluated using Pearson's product moment correlation coefficient. Cox univariate and multivariate proportional hazard models were used to assess the predictive power of CpG site methylation status. Sixteen CpG sites associated with PLAGL1 mRNA expression were identified in US and 6 in LMS. Statistical analyses revealed an association between CpG107 methylation status and both overall and metastasis-free survival in US, which was confirmed in a validation cohort of 37 US. The exhaustive study of P1 PLAGL1 promoter methylation identified a specific CpG site methylation correlated with mRNA expression, which was predictive for both metastasis-free and overall survival and may constitute the first US-specific biomarker. Such a biomarker may be relevant for identifying patients likely to derive greater benefit from treatment. 2013 Peille et al

Item Type: Article
Additional Information: pubid: 182 nvp_institute: NIBR contributor_address: (Peille, Lagarde, Le Morvan, Chibon, Bresson-Bepoldin) Institut Bergonie, Comprehensive Cancer Centre, Bordeaux, France (Peille, Lagarde, Le Morvan, Chibon, Bresson-Bepoldin) Univ. Bordeaux, Bordeaux, France (Peille, Lagarde, Le Morvan, Chibon, Bresson-Bepoldin) INSERM U916 VINCO, Bordeaux, France (Brouste) Clinical and Epidemiological Research Unit, Institut Bergonie, Comprehensive Cancer Centre, Bordeaux, France (Kauffmann) Department of Bioinformatics, Institut Bergonie, Comprehensive Cancer Centre, Bordeaux, France (Coindre, Chibon) Department of Biopathology, Institut Bergonie, Comprehensive Cancer Centre, Bordeaux, France (Peille) Oncotest GmbH, Freiburg, Germany (Kauffmann) Novartis Institutes for BioMedical Research, Disease Area Oncology, Basel, Switzerland
Date Deposited: 13 Oct 2015 13:12
Last Modified: 13 Oct 2015 13:12
URI: https://oak.novartis.com/id/eprint/22004

Search

Email Alerts

Register with OAK to receive email alerts for saved searches.